Envestnet Portfolio Solutions Inc. Makes New Investment in Grifols, S.A. (NASDAQ:GRFS)

Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Grifols, S.A. (NASDAQ:GRFS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,284 shares of the biotechnology company’s stock, valued at approximately $77,000.

A number of other hedge funds also recently made changes to their positions in GRFS. R Squared Ltd acquired a new stake in Grifols in the fourth quarter worth about $28,000. GAMMA Investing LLC lifted its stake in shares of Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,527 shares during the period. Blue Trust Inc. boosted its holdings in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 4,970 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Grifols during the fourth quarter valued at approximately $91,000. Finally, HighTower Advisors LLC raised its holdings in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 1,546 shares in the last quarter.

Grifols Price Performance

Shares of Grifols stock opened at $7.27 on Friday. Grifols, S.A. has a 52 week low of $5.79 and a 52 week high of $9.96. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The company’s 50-day moving average price is $7.56 and its two-hundred day moving average price is $8.05. The stock has a market cap of $5.00 billion, a PE ratio of 6.21 and a beta of 0.35.

Analysts Set New Price Targets

Separately, Morgan Stanley initiated coverage on Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.